$TSHA

Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

Taysha Gene Therapies (Nasdaq: TSHA) announced it will release its full-year 2025 financial results and host a conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. The clinical-stage biotechnology company focuses on AAV-based gene therapies for severe monogenic central nervous system diseases, with its lead program TSHA-102 targeting Rett syndrome. An archived replay of the webcast will be available on the company's website.

Original reporting
The Manila Times · GlobeNewswire
Published Mar 12, 2026, 12:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 12, 2026, 1:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 — source image
Decision brief

The 30-second read

$TSHANeutralMed
01

Why it matters

Upcoming financial results and webcast could influence investor sentiment and stock price, especially if results are significantly better or worse than expectations.

02

Market read

High relevance due to upcoming earnings and sector focus, likely to influence short-term trading activity.

03

What to watch

Potential regulatory developments or clinical trial updates could influence stock performance independently of financial results.

Timing: High, as the event is scheduled for March 19, 2026.

Background

Taysha Gene Therapies is a clinical-stage biotech focusing on AAV-based gene therapies for CNS diseases, with its lead program targeting Rett syndrome.

Company-level read

Ticker impact

$TSHANeutralMedium confidence
Context

High relevance due to upcoming financial results and focus on gene therapies for CNS diseases.

Expected impact

Limited immediate impact; potential for positive movement if results surpass expectations.

Evidence & confidence

Financial disclosures often lead to short-term volatility; however, without prior performance data, impact remains uncertain.

Market effects

Positive outlook for biotech and gene therapy sectors; potential spill-over effects on related biotech stocks.

Primarily US-based market impact; limited regional influence.

Moderate, as biotech is a globally relevant sector, but specific to US-listed company.

Counterpoint

Results may be below expectations, leading to short-term declines; market may have already priced in optimism.

Key entities

  • Taysha Gene Therapies

    A biotech company specializing in gene therapies for CNS diseases.

Related articles

$TSHAMed

Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In

Taysha Gene Therapies (NASDAQ:TSHA) priced an underwritten public offering of 32.5M shares at $6 each on June 24, plus prepaid warrants for 833,333 shares at $5.999 per warrant. The company expects about $200M gross proceeds and a 30-day option for up to 5M more shares. Bank of America raised its TSHA target to $10 from $9 and reiterated Buy after Part A REVEAL Rett syndrome study updates.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.